Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Phase I clinical trial results presented at the 2014 American Society of Clinical Oncology (ASCO) national meeting showed that veliparib is effective against breast and ovarian tumors in patients with BRCA mutations. In these patients the overall response rate was 29% for breast cancer and 20% for ovarian cancer. Of patients who did not have BRCA mutations, only triple-negative breast cancer patients experienced any benefit. The most common adverse effects were mild and included nausea and fatigue. Responses were higher with higher doses.
BROCADE3 is a phase III clinical trial for patients with a BRCA mutation and HER2-negative metastatic or locally advanced breast cancer. The study is comparing whether adding veliparib to treatment with two chemotherapy medicines (carboplatin and paclitaxel) is more effective than chemotherapy alone. Patients will receive either a combination of veliparib, carboplatin, and paclitaxel, or a combination of carboplatin and paclitaxel along with a placebo.
Brightness Study is a Phase III clinical trial for patients with newly-diagnosed triple negative breast cancer. The study is comparing whether adding veliparib to neo-adjuvant chemotherapy with carboplatin is more effective than carboplatin alone. The study is ongoing but no longer recruiting patients.